PLX icon

Protalix BioTherapeutics

2.59 USD
+0.05
1.97%
At close Apr 2, 4:00 PM EDT
After hours
2.54
-0.05
1.93%
1 day
1.97%
5 days
3.60%
1 month
12.12%
3 months
31.47%
6 months
153.92%
Year to date
31.47%
1 year
108.87%
5 years
18.26%
10 years
-85.61%
 

About: Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Employees: 213

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

880% more call options, than puts

Call options by funds: $98K | Put options by funds: $10K

139% more capital invested

Capital invested by funds: $3.52M [Q3] → $8.4M (+$4.88M) [Q4]

33% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 9

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

2% more funds holding

Funds holding: 44 [Q3] → 45 (+1) [Q4]

1.32% more ownership

Funds ownership: 4.65% [Q3] → 5.97% (+1.32%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$15
479%
upside
Avg. target
$15
479%
upside
High target
$15
479%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
44% 1-year accuracy
24 / 54 met price target
479%upside
$15
Buy
Maintained
3 Feb 2025

Financial journalist opinion

Based on 8 articles about PLX published over the past 30 days

Neutral
PRNewsWire
1 week ago
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
CARMIEL, Israel , March 24, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that its management will be participating in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, to be held virtually March 25-26, 2025. iAccess Alpha hosts virtual investor conferences featuring companies recommended by investors.
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
Positive
Proactive Investors
1 week ago
Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMI
Protalix Biotherapeutics Inc (NYSE-A:PLX) chairman Eliot Forster joined Proactive to discuss the company's unique approach to drug manufacturing using plant cells instead of mammalian cells. He explained that this method enhances purity, sustainability, and reproducibility, setting Protalix apart in the biotech space.
Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMI
Positive
Proactive Investors
2 weeks ago
Protalix Biotherapeutics gains momentum: analysts see long-term upside
Protalix Biotherapeutics Inc (NYSE-A:PLX) reported increased product revenues for 2024, driven by higher sales of its Fabry disease treatment, Elfabrio, to partner Chiesi Rare Disease. The company's improving financial position and revenue outlook have analysts projecting further upside following the release of its full year 2024 results.
Protalix Biotherapeutics gains momentum: analysts see long-term upside
Positive
Proactive Investors
2 weeks ago
Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate
Protalix Biotherapeutics Inc (NYSE-A:PLX) reported record revenue from product sales in 2024, driven by growth across all major commercial partnerships, and provided updates on its clinical pipeline, including a promising gout treatment candidate. The biopharmaceutical company recorded $53 million in product revenue for the year ended December 31, 2024, a 31% increase from $40.4 million in 2023, with gains from sales to Chiesi, Pfizer, and Brazil.
Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate
Positive
Benzinga
2 weeks ago
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond
On Monday, Protalix BioTherapeutics, Inc. PLX reported fiscal 2024 earnings of 4 cents, beating the consensus of 1 cent.
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond
Neutral
Seeking Alpha
2 weeks ago
Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - President and Chief Executive Officer Eyal Rubin - Senior Vice President and Chief Financial Officer Conference Call Participants Ram Selvaraju - H.C. Wainwright John Vandermosten - Zach's SCR Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Fiscal Year 2024 Financial and Business Results Conference Call.
Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
2 weeks ago
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2024, and provided a business and clinical update.
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results
Neutral
PRNewsWire
3 weeks ago
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , March 10, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2024 and provide a business and clinical update on March 17, 2025.
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
Positive
Proactive Investors
1 month ago
Protalix Biotherapeutics poised for profitability as rare disease drug gains momentum
For a small biotech company, Protalix Biotherapeutics Inc (NYSE-A:PLX) is making a big impression with analysts and investors by targeting rare diseases with cutting-edge treatments. The New Jersey- and Israel-based company has emerged as a biotech underdog with strong tailwinds that analysts at HC Wainwright and Zacks Small Cap Research believe puts it the brink of sustainable profitability.
Protalix Biotherapeutics poised for profitability as rare disease drug gains momentum
Positive
Proactive Investors
1 month ago
Protalix Biotherapeutics gains momentum in the rare disease space: analysts
Protalix Biotherapeutics Inc (NYSE-A:PLX) has received bullish assessments from analysts at HC Wainwright and Zacks Small Cap Research, who see sustainable profitability on the horizon. Strong revenue growth from its flagship Fabry disease treatment, Elfabrio, and a robust pipeline have prompted price target increases, with HC Wainwright raising its outlook to $15 per share and Zacks maintaining a valuation of $14.
Protalix Biotherapeutics gains momentum in the rare disease space: analysts
Charts implemented using Lightweight Charts™